Keyphrases
Interferon-α (IFN-α)
100%
Recombinant Human
100%
Randomized Placebo-controlled Trial
100%
Hepatitis
100%
Interferon Therapy
100%
B-type
100%
Aminotransferase Activity
80%
Placebo
60%
Serum Aminotransferases
60%
Adverse Effects
20%
Disease Activity
20%
Liver Histology
20%
Prospective Randomized Trial
20%
Response to Therapy
20%
Hepatitis C
20%
Chronic Hepatitis C
20%
Complete Response
20%
Partial Response
20%
Long-term Response
20%
Subcutaneous Injection
20%
Hepatitis C Virus Antibodies
20%
Treatment Level
20%
Randomized Double-blind Controlled Trial
20%
Therapy Discontinuation
20%
Aminotransferase Levels
20%
Recombinant Interferon alpha-2b
20%
Non-A, non-B Hepatitis
20%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Interferon
100%
Human Interferon
100%
Aminotransferase
83%
Chronic Hepatitis C
16%
Gamma Interferon
16%
Disease Activity
16%
Hepatitis C Virus
16%
Subcutaneous Injection
16%
Virus Antibody
16%
Alpha2b Interferon
16%
Hepatitis Non A Non B
16%
Immunology and Microbiology
interferon
100%
Human Interferon
100%
Aminotransferase Blood Level
50%
Hepatitis C
16%
Virus Antibody
16%
Hepatitis C Virus
16%
Interferon Gamma
16%
Alpha2b Interferon
16%
Pretreatment
16%